Verdinexor: A new oral treatment option for canine lymphoma

Verdinexor: A new oral treatment option for canine lymphoma

1 hour of RACE approved CE

Watch On Demand

In this CE session, we’ll review the latest best practices for managing canine lymphoma. We’ll also talk about how the first FDA conditionally approved oral tablet for canine lymphoma, LAVERDIA™-CA1 (verdinexor), is giving veterinarians and dog owners more options and increasing access to cancer care.

Course Number: 843843
Hosted by

Dr David Bruyette

DVM, DACVIM (SAIM)

Dr David Bruyette
You'll learn:

  • Evolving protocols for canine lymphoma treatment

  • The role of primary care teams in treating lymphoma

  • How SINE drugs work and why they are different

  • When to consider LAVERDIA™-CA1 for lymphoma patients

  • Guidelines to optimize patient outcomes

You must be logged in to enroll in this CE event.

Anivive Insiders are eligible to enroll in continuing education events. Continuing education credits are automatically tracked and submitted to CE Broker so veterinary professionals can focus on what matters most, the patients.

- OR -